| 139-99-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• CAS: 139-99-1
• 化学式: C19H38NaO6S
• 分子量: 417.6
• InChiKey: MMMANYBSAQLKAW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.84
• 重原子数：
  27
• 可旋转键数：
  19
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  98.3
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Transdermal cream
  申请人：TherapeuticsMD, Inc.

  公开号：US10098894B2

  公开（公告）日：2018-10-16

  This disclosure relates to transdermal pharmaceutical compositions containing progesterone in combination with one or more solubilizing agents and penetration enhancers, wherein the pharmaceutical compositions are formulated as creams for topical administration. In some embodiments, the transdermal pharmaceutical compositions contain progesterone, a medium-chain oil, and d-limonene. In some embodiments, the transdermal pharmaceutical compositions contain progesterone, a medium-chain oil, a penetration enhancer (e.g., propylene glycol, a fatty acid ester of propylene glycol, a glycol ether), and optionally d-limonene. In certain embodiments, the pharmaceutical compositions further include estradiol. Methods for treating conditions associated with hormone deficiency in a subject are also described.

  本公开涉及含有黄体酮的透皮药物组合物与一种或多种增溶剂和渗透促进剂的组合，其中药物组合物配制成膏霜，用于局部给药。在某些实施方案中，透皮药物组合物含有黄体酮、中链油和 d-柠檬烯。在某些实施方案中，透皮药物组合物含有黄体酮、中链油、渗透促进剂（如丙二醇、丙二醇的脂肪酸酯、乙二醇醚），以及可选的 d-柠檬烯。在某些实施方案中，药物组合物还包括雌二醇。还描述了治疗与受试者激素缺乏有关的病症的方法。
• TRANSDERMAL CREAM
  申请人：TherapeuticsMD, Inc.

  公开号：EP3174542A1

  公开（公告）日：2017-06-07
• [EN] TRANSDERMAL CREAM<br/>[FR] CRÈME TRANSDERMIQUE
  申请人：THERAPEUTICSMD INC

  公开号：WO2016018993A1

  公开（公告）日：2016-02-04

  This disclosure relates to transdermal pharmaceutical compositions containing progesterone in combination with one or more solubilizing agents and penetration enhancers, wherein the pharmaceutical compositions are formulated as creams for topical administration. In some embodiments, the transdermal pharmaceutical compositions contain progesterone, a medium-chain oil, and d-limonene. In some embodiments, the transdermal pharmaceutical compositions contain progesterone, a medium-chain oil, a penetration enhancer (e.g., propylene glycol, a fatty acid ester of propylene glycol, a glycol ether), and optionally d-limonene. In certain embodiments, the pharmaceutical compositions further include estradiol. Methods for treating conditions associated with hormone deficiency in a subject are also described.